More specifically, AXL was identified as a potential therapeutic target in oral squamous cell carcinoma (OSCC) [4], Head and Neck squamous cell carcinoma (HNSCC) [5] and esophageal cancer [6], with poor prognosis correlated to high AXL expression. Here, AXL is linked to head and neck squamous cell carcinoma.